ArticleNature communications2024
Tumour-retained activated CCR7
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 50 citations in OpenAlex.
- High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.HemaSphere · 2026Article
- Targeting cancer-intrinsic protein neddylation bypasses the loss of JAK/STAT signaling and overcomes acquired resistance to immunotherapy.Research square · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting.Acta pharmacologica Sinica · 2026Review
- Enhanced tumor immunotherapy by nanovesicles derived from engineered DC-like M1 macrophage.Acta pharmaceutica Sinica. B · 2026Article
- FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.Journal for immunotherapy of cancer · 2026Article
- Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-Seq.Nature communications · 2026Article
- Pentose phosphate pathway fuels cGAS-STING signalling to boost function of intratumoral conventional dendritic cells.Nature communications · 2026Article
- The transcription factor EHF promotes the maturation and immunosuppression of conventional dendritic cells.Nature communications · 2026Article
- Intratumoral Three-Cell-Type Clusters Are a Conserved Feature of Endogenous Antitumor Immunity.Cancer immunology research · 2026Article
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs.Nature immunology · 2026Article
- Positioning and reversible suppression of CCR7Immunity · 2026Article
- DC subsets and states unraveled across human juxtatumoral and malignant tissues.Nature immunology · 2026Article
- Liver microenvironment-driven immunosuppressive niche in colorectal cancer liver metastasis and its therapeutic remodeling.Frontiers in immunology · 2026Review
- Identification of an Immunotherapy-Associated CD1cInternational journal of women's health · 2026Article
- Loss of SHP-1 in CD11cFrontiers in immunology · 2026Article
- The Role of Chemokine-Related Genes in Diffuse Large B-Cell Lymphoma Prognosis and Tumor Microenvironment Characteristics.Analytical cellular pathology (Amsterdam) · 2026Article
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
Tumour dendritic cells (DCs) internalise antigen and upregulate CCR7, which directs their migration to tumour-draining lymph nodes (dLN). CCR7 expression is coupled to an activation programme enriched in regulatory molecule expression, including PD-L1. However, the spatio-temporal dynamics of CCR7
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.